Board of Directors

Acting in the interest of shareholders
by setting high standards for employees, directors and management of the Company's business
sacha portrait officiel cravate.jpg

Sacha Loiseau, Ph.D
Founder, Chairman of the Board and CEO

Sacha Founded Mauna Kea Technologies in 2000

Sacha is the co-inventor of the probe-based Confocal Laser Endomicroscopy technology and conducted the development of the Cellvizio product line, raising over € 120m with private and public investors, including €56.5m through an IPO in July 2011 on the NYSE Euronext Paris stock exchange. In 2013, Sacha was named co-lead of France's Re-industrialization Plan for Medical Devices by the French President and then a member of the Committee for the Future of Medicine. Sacha has served as a mentor of the Polytechnique-Stanford Ignite Program for young MedTech entrepreneurs for several years. Sacha was instrumental in the foundation of the association Medtech in France, of which he is Vice-President.

Sacha started his career at the National Center for Space Studies (CNES) in Toulouse and at the Paris Observatory, then joined NASA's Jet Propulsion Laboratory (JPL) in Pasadena, California, as a research scientist. Sacha is a graduate of Ecole Polytechnique and holds a Ph.D. in Astrophysics and Optical Instrumentation from University Paris-Diderot. He is the author of multiple scientific papers and holds 7 international patents and was the 2018 recipient of the Marius Lavet Prize.


Christopher D. McFadden, CFA
Member of the Board
Chair of the compensation and nomination committee

Managing Director of Kohlberg Kravis Roberts (KKR), a global investment fund.

Prior to joining KKR, Mr. McFadden founded Canyon Healthcare Partners, a healthcare private equity firm and was a Senior Advisor to Athyrium Capital Management.  Previously, he was a Managing Partner at Health Evolution Partners and a Managing Director at Goldman Sachs, where he was a member of the Americas Special Situations Group (AmSSG) focused on healthcare private investing. Mr. McFadden serves as Chairman of InnovaTel Telepsychiatry and as a Board Member for ValueCentric.
Molly O'Neill 2.jpg

Molly O'Neill
Member of the Board

Experienced Global Healthcare Growth and Strategy Leader for St. George's University, Grenada since 2018.

Molly O’Neill is a recognized leader at some of the world’s most prestigious healthcare delivery systems, as well as ground-breaking product development achievements in the area of medical device and digital health. Ms. O’Neill brings over 30 years of experience in developing growth strategies to increase market share and revenues of academic, not for profit and investor owned health care organizations.
Prior to joining St. George’s University in 2018, she served as the chief commercial officer at Proteus Digital Health, where in November of 2017, the FDA approved the first digital medicine NDA for Abilify Mycite®, thereby opening a new path for innovation in the pharmaceutical industry where silicon and software are part of a drug.
Ms. O’Neill has also held senior leadership roles at Tenet Healthcare Corporation, Duke Medicine, Partners Healthcare, Ascension Health Care Network, and Inova Health System. She received her B.Sc. in Journalism and her M.S. in Health Care Administration from Virginia Commonwealth University/Medical College of Virginia.


Claire Biot
Member of the Board

Claire Biot is Vice President, Life Sciences Industry, Dassault Systèmes, where she is responsible for long-term growth strategy in Life Sciences and Healthcare, as well as go-to-market strategy with the existing portfolio of solutions.
Prior to joining Dassault Systèmes, she was Managing Director of Health Products and Technologies Central Agency, a subsidiary of Greater Paris University Hospitals (AP-HP). Previously, she was Head of Division, Health Products Pricing and Reimbursement at the French Ministry of Health.
In addition to engineering degrees from France’s Ecole Polytechnique and the Corps des mines program, Claire Biot earned a Master of Science degree in life sciences from Cold Spring Harbor Laboratory, NY, USA, and a PhD in immunology from the Institut Pasteur. 


Jacquelien ten Dam
Member of the Board
Chair of the Audit Committee

Jacquelien ten Dam is Chief Financial Officer at Mimetas where she is responsible for the Corporate Development and Finance activities.
Mimetas uses it proprietary organ-on-a-chip platform to unravel disease biology to find novel therapies. Prior to joining Mimetas she worked at Picnic, one of the most disruptive start-ups in the Netherlands, playing a key role in accelerating the company’s B2B business. She led the team that provides big data consultancy and ecommerce advice to FMCG companies such as PepsiCo, Unilever and AB InBev. 
Jacquelien started her career at Kempen & Co, a European investment bank where she advised in numerous international capital market transactions including IPOs, secondary fundraisings and M&A transactions for companies such as Galapagos, ALK and QIAGEN. Jacquelien holds an MSc. degree from Leiden University in Biomedical Sciences. She has lived and worked in the US (UCLA), India (Dr. Reddy’s Laboratories) and the Netherlands.

Find out more by downloading the
Cellvizio Product Brochure